1-2 of 2
Panayiotis G. Theodossiadis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study

Petros P. Sfikakis, MD, Vlassis Grigoropoulos, MD, Ioannis Emfietzoglou, MD, George Theodossiadis, MD, Nicholas Tentolouris, MD, Evi Delicha, PHD, Christina Katsiari, MD, Kleopatra Alexiadou, MD, Erifili Hatziagelaki, MD, Panayiotis G. Theodossiadis, MD
Journal: Diabetes Care
Diabetes Care 2010;33(7):1523–1528
https://doi.org/10.2337/dc09-2372
Published: 22 April 2010
View article titled, Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: <subtitle>A randomized, double-blind, placebo-controlled, crossover, 32-week study</subtitle>
Open the PDF for Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: <subtitle>A randomized, double-blind, placebo-controlled, crossover, 32-week study</subtitle> in another window
Journal Articles

Regression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti–Tumor Necrosis Factor Monoclonal Antibody Infliximab

Petros P. Sfikakis, MD, Nikos Markomichelakis, MD, George P. Theodossiadis, MD, Vlassis Grigoropoulos, MD, Nikos Katsilambros, MD, Panayiotis G. Theodossiadis, MD
Journal: Diabetes Care
Diabetes Care 2005;28(2):445–447
https://doi.org/10.2337/diacare.28.2.445
Published: 01 February 2005
View article titled, Regression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti–Tumor Necrosis Factor Monoclonal Antibody Infliximab
Open the PDF for Regression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti–Tumor Necrosis Factor Monoclonal Antibody Infliximab in another window